Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: Termination of a randomized trial Academic Article uri icon

Overview

MeSH Major

  • Energy Metabolism
  • Insulin
  • Insulin Resistance
  • Obesity

abstract

  • Neither ALVAC (vCP1452) nor low-dose daily IL-2 nor their combination prevented the relapse of viremia upon discontinuation of antiviral therapy.

publication date

  • January 26, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC1783674

Digital Object Identifier (DOI)

  • 10.1371/journal.pctr.0020005

PubMed ID

  • 17260026

Additional Document Info

start page

  • e5

volume

  • 2

number

  • 1